The article focuses on Haemonetics' Q2 earnings, comparing them to Wall Street estimates and the previous year's results. This is directly relevant to investors as it provides a measure of the company's financial performance and market expectations. However, without specific figures or context on whether the results were above or below expectations, the immediate impact on stock price is neutral.